InvestorsHub Logo
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

Re: genisi post# 655

Sunday, 06/26/2011 2:52:24 AM

Sunday, June 26, 2011 2:52:24 AM

Post# of 3990
Shire's Replagal is already the market leader for the treatment of Fabry disease and its new manufacturing facility in Lexington allows it to increase supply if needed.

http://www.bioportfolio.com/news/article/723496/European-Authorities-Approve-New-Manufacturing-Facility-For-Shire-s-Replagal-agalsidase-Alfa.html

As for Gaucher's disease market: "Shire anticipates regulatory agency submission of the VPRIV (velaglucerase alfa) manufacturing process at the new Lexington manufacturing facility by the end of 2011." Meaning more capacity around the time PLX should get approval.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PLX News